Synopsis
Synopsis
0
JDMF
0
VMF
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Arterenol
2. Levarterenol
3. Levonor
4. Levonorepinephrine
5. Levophed
6. Levophed Bitartrate
7. Noradrnaline Tartrate Renaudin
8. Noradrenaline
9. Noradrenaline Bitartrate
10. Norepinephrin D-tartrate (1:1)
11. Norepinephrine
12. Norepinephrine Bitartrate
13. Norepinephrine D-tartrate (1:1)
14. Norepinephrine Hydrochloride
15. Norepinephrine Hydrochloride, (+)-isomer
16. Norepinephrine Hydrochloride, (+,-)-isomer
17. Norepinephrine L-tartrate (1:1)
18. Norepinephrine L-tartrate (1:1), (+,-)-isomer
19. Norepinephrine L-tartrate (1:1), Monohydrate
20. Norepinephrine L-tartrate (1:1), Monohydrate, (+)-isomer
21. Norepinephrine L-tartrate (1:2)
22. Norepinephrine L-tartrate, (+)-isomer
23. Norepinephrine, (+)-isomer
24. Norepinephrine, (+,-)-isomer
1. Noradrenaline Bitartrate
2. 51-40-1
3. Noradrenalinebitartrate
4. Norepinephrine (tartrate)
5. Noradrenaline Acid Tartrate
6. L-norepinephrine Bitartrate
7. L-arterenol Bitartrate
8. L-noradrenaline Tartrate
9. Norartrinal Bitartrate
10. 3414-63-9
11. Norepinephrine Tartrate
12. L-noradrenaline D-bitartrate
13. (-)-norepinephrine Bitartrate
14. Noradrenaline Hydrogen Tartrate
15. Noradrenaline, Tartrate (1:1)
16. Nsc-169106
17. Levophed Bitartrate
18. Noradrealine
19. L-4-(2-amino-1-hydroxyethyl)-1,2-benzenediol Bitartrate
20. (+)-hydrogentartratebitartratesalt
21. Arterenol,hydrate
22. Arterenol, Hydrate
23. (-)-noradrenaline Tartrate
24. (-)-norepinephrine Tartrate
25. Schembl41601
26. (-)-arterenol Bitartrate Salt
27. Chembl2062273
28. (-)-noradrenaline Acid Tartrate
29. Bcbcmap01_000135
30. Norepinephrine Tartrate Impurity 1
31. Amy33378
32. Bcp31352
33. Nsc60394
34. (-)-noradrenaline Hydrogen Tartrate
35. (-)-norepinephrine (+)-bitartrate
36. Wln: Z1yqr Cq Dq &ovyqyqvo
37. Nsc-60394
38. Nsc169106
39. Akos015895170
40. L-(-)-norepinephrine (+)-bitartrate
41. Smp1_000021
42. (-)-noradrenaline Bitartrate Monohydrate
43. Ac-18753
44. Db-073364
45. N-8721
46. Sr-01000075279-1
47. Benzyl Alcohol,4-dihydroxy-, (-)-, Tartrate (1:1)
48. D-norepinephrine D-bitartrate;(+)-noradrenaline Bitartrate
49. L-(-)-norepinephrine-(+)-bitartrate - Cas 69815-49-2
50. Benzyl Alcohol,4-dihydroxy-, (-)-, Tartrate (1:1) (salt)
51. 4-(2-amino-1-hydroxyethyl)benzene-1,2-diol;2,3-dihydroxybutanedioic Acid
52. 1, 4-(2-amino-1-hydroxyethyl)-, (r)-, [r-(r*,r*)]-2,3-dihydroxybutanedioate (1:1) (salt)
Molecular Weight | 319.26 g/mol |
---|---|
Molecular Formula | C12H17NO9 |
Hydrogen Bond Donor Count | 8 |
Hydrogen Bond Acceptor Count | 10 |
Rotatable Bond Count | 5 |
Exact Mass | 319.09033112 g/mol |
Monoisotopic Mass | 319.09033112 g/mol |
Topological Polar Surface Area | 202 Ų |
Heavy Atom Count | 22 |
Formal Charge | 0 |
Complexity | 276 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 3 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Adrenergic alpha-Agonists
Drugs that selectively bind to and activate alpha adrenergic receptors. (See all compounds classified as Adrenergic alpha-Agonists.)
Sympathomimetics
Drugs that mimic the effects of stimulating postganglionic adrenergic sympathetic nerves. Included here are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters. (See all compounds classified as Sympathomimetics.)
Vasoconstrictor Agents
Drugs used to cause constriction of the blood vessels. (See all compounds classified as Vasoconstrictor Agents.)
Malladi is a leader in Ephedrine, Pseudoephedrine Salts & Phenylephrine HCl // USFDA, EDQM, ANSM, KFDA, and TGA inspected.
Certificate Number : R1-CEP 2004-312 - Rev 01
Issue Date : 2021-12-10
Type : Chemical
Substance Number : 285
Status : Valid
Available Reg Filing : ROW |
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 35184
Submission : 2021-02-22
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2019-09-04
Pay. Date : 2019-07-11
DMF Number : 34008
Submission : 2019-07-31
Status : Active
Type : II
Certificate Number : R0-CEP 2020-089 - Rev 00
Issue Date : 2021-06-08
Type : Chemical
Substance Number : 285
Status : Valid
GDUFA
DMF Review : Reviewed
Rev. Date : 2019-11-19
Pay. Date : 2019-09-19
DMF Number : 33127
Submission : 2018-09-30
Status : Active
Type : II
Certificate Number : R0-CEP 2022-253 - Rev 00
Issue Date : 2023-08-08
Type : Chemical
Substance Number : 285
Status : Valid
Date of Issue : 2022-06-06
Valid Till : 2025-07-21
Written Confirmation Number : WC-0044
Address of the Firm :
NDC Package Code : 66064-1025
Start Marketing Date : 2017-02-01
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (5kg/5kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-01-03
Pay. Date : 2013-12-20
DMF Number : 16344
Submission : 2002-12-20
Status : Active
Type : II
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Levophed-Generic (norepinephrine bitartrate) is an adrenergic receptor agonist, small molecule drug candidate. Along with Dextrose it is indicated for the treatment of severe, acute hypotension
Lead Product(s): Norepinephrine Bitartrate,Dextrose
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Levophed-Generic
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 20, 2021
Lead Product(s) : Norepinephrine Bitartrate,Dextrose
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Levophed-Generic (norepinephrine bitartrate) is an adrenergic receptor agonist, small molecule drug candidate. Along with Dextrose it is indicated for the treatment of severe, acute hypotension
Brand Name : Levophed-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 20, 2021
Details:
Norepinephrine Bitartrate is an adrenergic receptor agonist, small molecule drug candidate. Along with Dextrose it is indicated for the treatment of severe, acute hypotension.
Lead Product(s): Norepinephrine Bitartrate,Dextrose
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 11, 2024
Lead Product(s) : Norepinephrine Bitartrate,Dextrose
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Baxter Expands Pharmaceuticals Portfolio with New Injectable Products in the U.S.
Details : Norepinephrine Bitartrate is an adrenergic receptor agonist, small molecule drug candidate. Along with Dextrose it is indicated for the treatment of severe, acute hypotension.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 11, 2024
Details:
Under the agreement, Long Grove Pharmaceuticals in-licensed Norepinephrine Bitartrate in 0.9% Sodium Chloride premix formulation, indicated to raise blood pressure in adult patients with severe, acute hypotension, from Nevakar Injectables.
Lead Product(s): Norepinephrine Bitartrate
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: NVK004
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Long Grove Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 04, 2023
Lead Product(s) : Norepinephrine Bitartrate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Long Grove Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Long Grove Pharmaceuticals Secures Commercial Rights to an Essential Critical Care Medication
Details : Under the agreement, Long Grove Pharmaceuticals in-licensed Norepinephrine Bitartrate in 0.9% Sodium Chloride premix formulation, indicated to raise blood pressure in adult patients with severe, acute hypotension, from Nevakar Injectables.
Brand Name : NVK004
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 04, 2023
(2-Chloro 3,4-Dihydroxy Acetophenone)
CAS Number : 99-40-1
End Use API : Norepinephrine Bitartrate
About The Company : Vital Group of companies is a leading Manufacturer and Exporter of Active Pharmaceutical Ingredients (API). Founded in 1999 Vital set up a unit for manufacturin...
Regulatory Info : RX
Registration Country : USA
Brand Name : NOREPINEPHRINE BITARTRATE
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : EQ 1MG BASE/ML
Packaging :
Approval Date : 2021-01-22
Application Number : 214455
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
Brand Name : NOREPINEPHRINE BITARTRATE
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : EQ 1MG BASE/ML
Packaging :
Approval Date : 2012-03-27
Application Number : 40859
Regulatory Info : RX
Registration Country : USA
Regulatory Info : Ethical
Registration Country : Canada
NOREPINEPHRINE (NOREPINEPHRINE BITARTRATE)
Brand Name : NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE INJECTION
Dosage Form : SOLUTION
Dosage Strength : 0.016MG/ML
Packaging :
Approval Date :
Application Number : 2501430
Regulatory Info : Ethical
Registration Country : Canada
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Injection
Dosage Strength : 1MG/ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Regulatory Info : RX
Registration Country : USA
Brand Name : NOREPINEPHRINE BITARTRATE
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : EQ 1MG BASE/ML
Packaging :
Approval Date : 2020-11-03
Application Number : 211382
Regulatory Info : RX
Registration Country : USA
Regulatory Info : Ethical
Registration Country : Canada
NOREPINEPHRINE (NOREPINEPHRINE BITARTRATE)
Brand Name : NOREPINEPHRINE BITARTRATE INJECTION USP
Dosage Form : SOLUTION
Dosage Strength : 1MG/ML
Packaging :
Approval Date :
Application Number : 2485680
Regulatory Info : Ethical
Registration Country : Canada
Regulatory Info : RX
Registration Country : USA
Brand Name : LEVOPHED
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : EQ 1MG BASE/ML
Packaging :
Approval Date : 1982-01-01
Application Number : 7513
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
Brand Name : NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE
Dosage Form : SOLUTION;INTRAVENOUS
Dosage Strength : EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)
Packaging :
Approval Date : 2022-10-06
Application Number : 214628
Regulatory Info : RX
Registration Country : USA
Regulatory Info : DISCN
Registration Country : USA
Brand Name : NOREPINEPHRINE BITARTRATE
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : EQ 1MG BASE/ML
Packaging :
Approval Date : 2022-07-19
Application Number : 216341
Regulatory Info : DISCN
Registration Country : USA
Regulatory Info :
Registration Country : Italy
Lidocaine Hydrochloride; Norepinephrine bitartrate
Brand Name : Lidocaine Hydrochloride With Norepinephrine Bitartrate
Dosage Form :
Dosage Strength : 50 Vials 200 Mg/10 Ml + 0.2 Mg/10 Ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Related Excipient Companies
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?